You are here

chronic cough

FDA panel flags insufficient data for Merck's chronic cough drug

FDA panel flags insufficient data for Merck's chronic cough drug

Reuters

Flag link:

FDA skeptical of Merck’s gefapixant, even after cough recount

FDA skeptical of Merck’s gefapixant, even after cough recount

Fierce Biotech

Flag link:

Aldeyra's roller coaster month ends with 'positive' phase 2 chronic cough readout

Aldeyra's roller coaster month ends with 'positive' phase 2 chronic cough readout

Fierce Biotech

Aldeyra Therapeutics

clinical trials

Flag link:

GSK coughs up $2B for Bellus Health

GSK coughs up $2B for Bellus Health

Medical Marketing and Media

Flag link:

Merck plans to count coughs and months until gefapixant is back in FDA hands

Merck plans to count coughs and months until gefapixant is back in FDA hands

Fierce Biotech

Flag link:

Merck: FDA Rejects Gefapixant Application, Requests More Data

Merck: FDA Rejects Gefapixant Application, Requests More Data

Marketwatch

Flag link:

Bellus soars on positive mid-stage readout for its Merck cough rival, despite a failure in atopic dermatitis

Bellus soars on positive mid-stage readout for its Merck cough rival, despite a failure in atopic dermatitis

Endpoints

Flag link:

Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough

Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough

Fierce Biotech

ViiV Healthcare

clinical trials

Flag link:

Bellus says its Merck cough rival passed a PhIIb test after earlier flop, but investors can't make up their minds

Bellus says its Merck cough rival passed a PhIIb test after earlier flop, but investors can't make up their minds

Endpoints

clinical trials

Flag link:

FDA says it needs a little more time to decide on Merck's P2X3 for chronic cough

FDA says it needs a little more time to decide on Merck's P2X3 for chronic cough

Endpoints

Flag link:

Chasing Merck & Co, Bayer builds case for cough drug eliapixant

Chasing Merck & Co, Bayer builds case for cough drug eliapixant

Pharmaforum

clinical trials

Flag link:

Merck's gefapixant successful in late-stage chronic cough studies

Merck's gefapixant successful in late-stage chronic cough studies

Seeking Alpha

clinical trials

Flag link:

Bellus hit with a setback as its PhII chronic cough drug flops on all 4 doses -- shares cremated on Wall Street

Bellus hit with a setback as its PhII chronic cough drug flops on all 4 doses -- shares cremated on Wall Street

Endpoints

clinical trials

Flag link:

Merck hits goal in cough phase 3 but yet to quash tolerability concern

Merck hits goal in cough phase 3 but yet to quash tolerability concern

Fierce Biotech

clinical trials

Flag link:

Bellus hopes to fuel up on IPO cash as it squares off with giant Merck on a rival drug

Bellus hopes to fuel up on IPO cash as it squares off with giant Merck on a rival drug

Endpoints

Flag link:

NeRRe hopes to advance cough candidate despite Phase II miss

NeRRe hopes to advance cough candidate despite Phase II miss

BioCentury

clinical trials

Flag link:

Evotec Receives Milestone Payment for Initiating Ph II Trials of Persistent Cough Drug

Evotec Receives Milestone Payment for Initiating Ph II Trials of Persistent Cough Drug

CP Wire

Flag link: